Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Chemotherapeutics in the treatment of multiple sclerosis.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Cladribine exerts an immunomodulatory effect on human and murine dendritic cells.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53.
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.
Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
US and EU regulatory authorities accept PLEGRIDY™ (peginterferon beta-1a) marketing applications for review
Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study.
Oracle Cladribine in Early Multiple Sclerisis (MS) (ORACLE MS)
Chronic cladribine administration increases amyloid Beta Peptide generation and plaque burden in mice.
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial.
Intas launches biosimilar version of Rituximab
Architecture of human mTOR complex 1.
Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial.
IFN-β inhibits T cells accumulation in the central nervous system by reducing the expression and activity of chemokines in experimental autoimmune encephalomyelitis.
Refining diagnosis of multiple sclerosis with revised MRI criteria.
A One Year Follow-Up Study of Natural Killer and Dendritic Cells Activities in Multiple Sclerosis Patients Receiving Glatiramer Acetate (GA).
Genzyme provides update on U.S. LEMTRADA™ filing
Mitoxantrone-related acute leukemia in MS: An open or closed book?
Changes in B- and T-lymphocyte and chemokine levels with rituximab treatment in multiple sclerosis.
Glatiramer acetate biases dendritic cells towards an anti-inflammatory phenotype by modulating OPN, IL-17, and RORγt responses and by increasing IL-10 production in experimental allergic encephalomyelitis.

Pages